Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Cancer- and cancer treatment-related conditions
Stage/Subtype:  graft versus host disease
Trial Type:  Supportive care
Results 1-25 of 50 for your search:
Start Over
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Alpha 1 Anti-Trypsin in Treating Patients with Acute Graft-Versus-Host Disease
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: not specified
Trial IDs: 2571.00, NCI-2011-03805, 2571, NCT01523821
Chemotherapy and Donor Lymphocytes in Treating Older Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 55 and over
Trial IDs: Pro00043247, NCI-2014-00663, NCT02046122
Recombinant Human Chorionic Gonadotropin in Supporting Tolerance and Repairs in Patients with High-Risk or Refractory to Acute Graft Versus Host Disease
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 12 to 76
Trial IDs: 2014LS020, NCI-2015-02022, MT2014-12, NCT02525029
Baricitinib in Treating Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 to 99
Trial IDs: 16-C-0094, NCI-2016-00773, NCT02759731
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients with High-Risk Hematological Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Pomalidomide in Treating Patients with Chronic Graft-versus-Host Disease
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 75
Trial IDs: 12-C-0197, NCI-2013-01552, 120197, P12974, NCT01688466
Abatacept, Cyclosprine, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease in Patients with High-Risk Leukemia Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 and over
Trial IDs: 2692.00, NCI-2016-00220, PBMTC PROTOCOL GVH 1201, NCT01743131
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 21 and under
Trial IDs: 2660.00, NCI-2013-00958, 2660, NCT01858740
Cyclophosphamide in Preventing Graft-versus-Host Disease after Donor Stem Cell Transplant in Patients with Hematopoietic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care
Age: 19 to 65
Trial IDs: UAB1286, NCI-2015-00251, NCT02065154
Topical Sirolimus in Treating Patients with Refractory Oral Chronic Graft-versus-Host Disease
Status: Active
Phase: Phase II
Type: Supportive care
Age: 4 and over
Trial IDs: 14-090, NCI-2014-01564, NCT02123966
Pasireotide in Reducing Gastrointestinal Toxicity from Chemotherapy and Radiation Therapy in Patients Undergoing a Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00051736, NCI-2014-02316, NCT02215070
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Supportive care
Age: 55 and over
Trial IDs: CLT008-03, NCI-2014-02461, NCT02282215
Biomarkers in Predicting Treatment Outcome in Patients with Acute GVHD Treated with and without Extracorporeal Photopheresis
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 15-C-0039, NCI-2015-00092, 150039, 339918, P141598, NCT02322190
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 to 75
Trial IDs: 13494, NCI-2015-00283, 118207, 118814, 119250, 121375, NCT02396134
Patient-Centered Home Based Care in Reducing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: Pro00051024, NCI-2014-01942, NCT02218151
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: GS-US-406-1840, NCI-2016-00628, 2015-004572-30, NCT02701634
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: Any age
Trial IDs: BMTCTN1501, NCI-2016-00996, 2U10HL069294-11, 5U24CA076518, NCT02806947
Tacrolimus, Bortezomib, and Anti-thymocyte Globulin in Preventing Low Toxicity GVHD in Patients with Blood Cancer Undergoing Donor Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Prevention, Supportive care, Treatment
Age: 18 to 75
Trial IDs: Winship3258-16, NCI-2016-01035, IRB00082499, NCT02877082
Dietary Intervention in Preventing Acute Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Prevention, Supportive care
Age: 10 and over
Trial IDs: UMCC 2016.029, NCI-2016-01415, NCT02763033
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Status: Not yet active
Phase: Phase II
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: INCB 18424-271, NCI-2016-01824, INCB 18424-271/REVERSE-1, NCT02953678
Biological Therapy and Gene Therapy in Improving Immune System Recovery After Stem Cell Transplant in Patients With Hematopoietic Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: DOTTI, NCI-2012-01076, H-28256, NCT01494103
Natural Killer Cells and Donor Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Status: Active
Phase: Phase I
Type: Supportive care, Treatment
Age: 18 to 59
Trial IDs: 2011-0493, NCI-2012-02071, NCT01619761
Start Over